An orally delivered small-molecule formulation with antiangiogenic and anticancer activity (Nat Biotechnol, 2008, 26:799-807)

報告日期: 2008/12/09
報告時間: 16:00/16:50
報告學生: 黃彥彰
講評老師: 陳玉玲
附件下載:

http://basicmed.med.ncku.edu.tw/admin/up_img/971209-2.pdf

An orally delivered small-molecule formulation with

antiangiogenic and anticancer activity

NATURE BIOTECHNOLOGY VOLUME 26 NUMBER 7 JULY 2008

 

Speaker: 黃彥彰

Commentator: 陳玉玲 老師

Date: 2008/12/9

Time: 16:10~17:00

 

Abstract

Angiogenesis inhibition is an important modality for cancer therapy. TNP-470 is an analog of fumagillin, which is among the most potent

inhibitors of angiogenesis. It has show its ability to slow tumor progression or cause durable complete regression either given as a single agent, or in combination with other conventional chemotherapeutic drugs. But neural side-effects, extremely short plasma half-life and poor oral availability limit its effects in the clinic. The authors have addressed these issues and report an oral formulation of TNP-470, named Lodamin. TNP-470 was conjugated to monomethoxy-polyethylene glycol–polylactic acid to form nanopolymeric micelles. Using the oral route of administration, it first reaches the liver, making it especially efficient in preventing the development of liver metastasis in mice. The authors show that Lodamin is an oral nontoxic antiangiogenic drug that can be chronically administered for cancer therapy or metastasis prevention.

Reference

Almog, N. et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 20, 947–949 (2006).